These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 17374422)

  • 1. C57Bl/6 mice are protected from respiratory syncytial virus (RSV) challenge and IL-5 associated pulmonary eosinophilic infiltrates following intranasal immunization with Protollin-eRSV vaccine.
    Cyr SL; Jones T; Stoica-Popescu I; Burt D; Ward BJ
    Vaccine; 2007 Apr; 25(16):3228-32. PubMed ID: 17374422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal proteosome-based respiratory syncytial virus (RSV) vaccines protect BALB/c mice against challenge without eosinophilia or enhanced pathology.
    Cyr SL; Jones T; Stoica-Popescu I; Brewer A; Chabot S; Lussier M; Burt D; Ward BJ
    Vaccine; 2007 Jul; 25(29):5378-89. PubMed ID: 17561317
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR4 and MyD88 control protection and pulmonary granulocytic recruitment in a murine intranasal RSV immunization and challenge model.
    Cyr SL; Angers I; Guillot L; Stoica-Popescu I; Lussier M; Qureshi S; Burt DS; Ward BJ
    Vaccine; 2009 Jan; 27(3):421-30. PubMed ID: 19013492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine host responses to respiratory syncytial virus (RSV) following intranasal administration of a Protollin-adjuvanted, epitope-enhanced recombinant G protein vaccine.
    Huang Y; Cyr SL; Burt DS; Anderson R
    J Clin Virol; 2009 Apr; 44(4):287-91. PubMed ID: 19233722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of mucosal B-cell memory by intranasal immunization of mice with respiratory syncytial virus.
    Valosky J; Hishiki H; Zaoutis TE; Coffin SE
    Clin Diagn Lab Immunol; 2005 Jan; 12(1):171-9. PubMed ID: 15643003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-lasting balanced immunity and protective efficacy against respiratory syncytial virus in mice induced by a recombinant protein G1F/M2.
    Zeng R; Qi X; Gong W; Mei X; Wei L; Ma C; Yin X
    Vaccine; 2007 Oct; 25(42):7422-8. PubMed ID: 17850930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.
    Benoit AC; Huang Y; Maneewatchararangsri S; Tapchaisri P; Anderson R
    Vaccine; 2007 Nov; 25(45):7754-62. PubMed ID: 17920164
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual proinflammatory and antiviral properties of pulmonary eosinophils in respiratory syncytial virus vaccine-enhanced disease.
    Su YC; Townsend D; Herrero LJ; Zaid A; Rolph MS; Gahan ME; Nelson MA; Rudd PA; Matthaei KI; Foster PS; Dent L; Tripp RA; Lee J; Simson L; Mahalingam S
    J Virol; 2015 Feb; 89(3):1564-78. PubMed ID: 25410867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.
    Garlapati S; Garg R; Brownlie R; Latimer L; Simko E; Hancock RE; Babiuk LA; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Vaccine; 2012 Jul; 30(35):5206-14. PubMed ID: 22713718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
    Johnson TR; Graham BS
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S46-57. PubMed ID: 14730270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prime-boost vaccination strategy using attenuated Salmonella typhimurium and a replication-deficient recombinant adenovirus vector elicits protective immunity against human respiratory syncytial virus.
    Fu YH; He JS; Wang XB; Zheng XX; Wu Q; Xie C; Zhang M; Wei W; Tang Q; Song JD; Qu JG; Hong T
    Biochem Biophys Res Commun; 2010 Apr; 395(1):87-92. PubMed ID: 20350532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.
    Mottram PL; Leong D; Crimeen-Irwin B; Gloster S; Xiang SD; Meanger J; Ghildyal R; Vardaxis N; Plebanski M
    Mol Pharm; 2007; 4(1):73-84. PubMed ID: 17274665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus.
    Jiao YY; Fu YH; Yan YF; Hua Y; Ma Y; Zhang XJ; Song JD; Peng XL; Huang J; Hong T; He JS
    Antiviral Res; 2017 Aug; 144():57-69. PubMed ID: 28529001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge.
    Antonis AF; van der Most RG; Suezer Y; Stockhofe-Zurwieden N; Daus F; Sutter G; Schrijver RS
    Vaccine; 2007 Jun; 25(25):4818-27. PubMed ID: 17499893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of repeated respiratory syncytial virus infections on pulmonary dendritic cells in a murine model of allergic asthma.
    Hirose H; Matsuse H; Fukahori S; Tsuchida T; Tomari S; Kawano T; Fukushima C; Mizuta Y; Kohno S
    Int Arch Allergy Immunol; 2008; 147(3):197-205. PubMed ID: 18594149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response of calves to challenge exposure with virulent bovine respiratory syncytial virus following intranasal administration of vaccines formulated for parenteral administration.
    Ellis J; Gow S; West K; Waldner C; Rhodes C; Mutwiri G; Rosenberg H
    J Am Vet Med Assoc; 2007 Jan; 230(2):233-43. PubMed ID: 17223757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.